Published online before print February 2, 2006, doi: 10.1161/01.ATV.0000206211.21895.73
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Effect of Modified C-Reactive Protein on Complement Activation
A Possible Complement Regulatory Role of Modified or Monomeric C-Reactive Protein in Atherosclerotic Lesions
From the Institute of Biophysics (S.-R.J., Y.W., Y.-H.L., J.Z.), Lanzhou University, P. R. China; and Immtech International Inc. (L.A.P.), Vernon Hills, Ill.
Correspondence to Yi Wu, Institute of Biophysics, Lanzhou University, Lanzhou 730000, P. R. China. E-mail wuy{at}lzu.edu.cn
Objective— The capacity of human C-reactive protein (CRP) to activate/regulate complement may be an important characteristic that links CRP and inflammation with atherosclerosis. Recent advances suggest that in addition to classical pentameric CRP, a conformationally distinct isoform of CRP, termed modified or monomeric CRP (mCRP), may also play an active role in atherosclerosis. Although the complement activation behavior of CRP has been well established, the capacity of mCRP to interact with and activate the complement cascade is unknown.
Methods and Results— mCRP bound avidly to purified C1q, and this binding occurred primarily through collagen-like region of C1q. Fluid phase mCRP inhibited the activation of complement cascade via engaging C1q from binding with other complement activators. In contrast, when immobilized or bound to oxidized or enzymatically modified low-density lipoprotein, mCRP could activate classical complement pathway. Low-level generation of sC5b-9 indicated that the activation largely bypassed the terminal sequence of complement, which appears to involve recruitment of Factor H.
Conclusions— These results indicate that mCRP can both inhibit and activate the classical complement pathway by binding C1q, depending on whether it is in fluid phase or surface-bound state.
The current work studied interaction of mCRP with complement. Our data showed that mCRP can both inhibit and activate the classical complement pathway by binding C1q, depending on whether it is in fluid phase or surface bound.
Key Words: modified C-reactive protein • complement • low-density lipoprotein
This article has been cited by other articles:
 |
|
 |
|
  S.-R. Ji, L. Ma, C.-J. Bai, J.-M. Shi, H.-Y. Li, L. A. Potempa, J. G. Filep, J. Zhao, and Y. Wu Monomeric C-reactive protein activates endothelial cells via interaction with lipid raft microdomains FASEB J, June 1, 2009; 23(6): 1806 - 1816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Ho, C. D. Owens, T. Longo, X. X. Sui, C. Ifantides, and M. S. Conte C-reactive protein and vein graft disease: evidence for a direct effect on smooth muscle cell phenotype via modulation of PDGF receptor-{beta} Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1132 - H1140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Shagdarsuren, K. Bidzhekov, Y. Djalali-Talab, E. A. Liehn, M. Hristov, R. A. Matthijsen, W. A. Buurman, A. Zernecke, and C. Weber C1-Esterase Inhibitor Protects Against Neointima Formation After Arterial Injury in Atherosclerosis-Prone Mice Circulation, January 1, 2008; 117(1): 70 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G O'Neill, D. A Isenberg, and A. Rahman Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus? Ann Rheum Dis, August 1, 2007; 66(8): 989 - 991. [Full Text] [PDF]
|
|
|
|
|
|
S.-R. Ji, Y. Wu, L. Zhu, L. A. Potempa, F.-L. Sheng, W. Lu, and J. Zhao Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRPm FASEB J, January 1, 2007; 21(1): 284 - 294. [Abstract] [Full Text] [PDF]
|
|